Caprock Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Caprock Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,887	Closed	-$285K	–	1206
2025 Q3	$285K	Buy	+4,887	New	+$279K	0.01%	958
2025 Q1	$218K	Buy	+3,087	New	+$208K	0.01%	982
2023 Q2	–	Sell	-2,065	Closed	-$201K	–	665
2023 Q1	$201K	Buy	2,065 +118	+6%	+$12.2K	0.02%	597
2022 Q4	$201K	Buy	+1,947	New	+$183K	0.02%	509

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Caprock Group's BMRN Position: Q4 2025 in Review

Caprock Group sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4,887 shares — an estimated $285K sold.

Caprock Group first reported a position in BMRN in Q4 2022 and held it in 4 quarters. The position peaked at $285K in Q3 2025. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Caprock Group reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Caprock Group sold 4,887 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $285K.
Caprock Group first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 4 quarters.
Caprock Group's BioMarin Pharmaceuticals position peaked at $285K in Q3 2025.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Caprock Group's 13F filing for Q4 2025, filed 28 Jan 2026.